Huss-Marp Johannes, Raulf Monika, Jakob Thilo
Allergy Research Group, Department of Dermatology, University Medical Center Freiburg, Freiburg, Germany ; AbbVie Deutschland GmbH & Co. KG, Mainzer Straße 81, 65189 Wiesbaden, Germany.
Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum, Bochum, Germany.
Allergo J Int. 2015;24:236-243. doi: 10.1007/s40629-015-0072-2. Epub 2015 Nov 7.
Essentially, allergen components offer three possibilities to improve in vitro IgE diagnostics: Allergen components can be used individually for IgE determination.Allergen components can be combined as a mix in one test.Individual allergen components can be specifically added to the extract. Option (a) is currently being used most extensively in practice, while (b) represents more of a theoretical possibility. The specific addition ("spiking") of allergen components to an allergy extract (c) has been performed in the past for the ImmunoCAP® tests for latex (09/2001), hazelnut (05/2006) and wasp venom (06/2012). Through this approach under-represented allergen components could be compensated and the analytical sensitivity of the test systems significantly increased. In combined use with molecular Singleplex tests, these modified tests allow for new diagnostic possibilities. Clear communication from the manufacturer regarding in which test and from what time point on, recombinant allergens were added - and where this was not done despite under-represented allergen components - is important for the interpretation of the test results in routine clinical practice.
从本质上讲,变应原成分提供了三种改进体外IgE诊断的可能性:变应原成分可单独用于IgE测定。变应原成分可在一项检测中作为混合物组合使用。可将单个变应原成分特异性添加到提取物中。选项(a)目前在实践中应用最为广泛,而(b)更多是一种理论上的可能性。过去,针对乳胶(2001年9月)、榛子(2006年5月)和黄蜂毒液(2012年6月)的ImmunoCAP®检测,已将变应原成分特异性添加(“加标”)到过敏提取物中(c)。通过这种方法,可以补偿含量不足的变应原成分,并显著提高检测系统的分析灵敏度。与分子单重检测联合使用时,这些改良检测提供了新的诊断可能性。制造商就重组变应原添加到了哪种检测中以及从哪个时间点开始添加——以及在变应原成分含量不足时未进行添加的情况——进行明确说明,对于常规临床实践中检测结果的解读很重要。